Article Text

PDF
AB0683 Hip Involvement in Spondyloarthritis Patients: A Frequent and Serious Manifestation
  1. F. Aguiar,
  2. T. Martins-Rocha,
  3. R. Fonseca,
  4. A. Bernardo,
  5. I. Brito
  1. Rheumatology, Centro Hospitalar São João, Oporto, Portugal

Abstract

Background The prevalence of hip involvement in spondyloarthritis (SpA) patients varies from 7–50%. It is a cause of significant functional impairment and a marker of poor prognosis.

Objectives The aim of this study was to compare demographic, clinical, laboratory and treatment data among SpA patients with and without hip involvement.

Methods Cross-sectional study including 187 SpA patients that fullfilled the modified New York criteria. The patients completed a questionnaire assessing age at diagnosis, disease subtype, clinical presentation, disease-activity (BASDAI, ASDAS) and functional-indices (BASFI) and BASMI was calculated. The patients' records were consulted to asses the following parameters: presence of HLA-B27 antigen, inflammatory markers (ESR, CRP), radiographs of spine, hip and sacroiliac joints. Hip involvement was considered based on the BASRI-hip scoring system (hip involvement if ≥2). The statistical analysis was performed using SPSS 21.0 software, and p<0.05 was taken to indicate statistical significance. To compare the differences between the groups, Mann-Whitney U, χ2 and Fisher tests were used.

Results 187 patients were included, with 55.6% males, median age 46.0 (range 21.0–79.0) years. In this study 75 (40.1%) patients had hip involvement, which was significantly more frequent in males (46.1% vs 32.5%, p=0.041). There were no statistically significant differences in age at diagnosis, age at evaluation, time of diagnosis, smoking habits, subtype of SpA, extra-articular manifestations or HLA-B27 positivity. Ankylosis of bilateral sacroiliac joints and syndesmophytosis were significantly more frequent in patients with hip involvement (56.2 vs 28.8% p<0.001 and 57.3% vs 38.7% p=0.009). Median disease duration was significantly greater in SpA patients with hip involvement (19.0 vs 14.0 years, p=0.001). BASMI, BASFI and ASDAS-CRP were significantly higher in patients with hip involvement (median 5.0 vs 3.8, p<0.001; median 5.1 vs 3.3, p=0.001 and 2.4 vs 2.0, p=0.038, respectively). Median BASDAI and ASDAS-ESR were also higher in these patients but this difference was not statistically significant (3.3 vs 2.8, p=0.361 and 2.3 vs 2.1 p=0.318, respectively). There were no differences in what concerns SpA treatment between the two groups.

Conclusions This study shows that radiographic hip involvement is a frequent disease manifestation in SpA, and that it could be more common in male patients with long-standing disease. It also confirms that hip involvement reflects more severe disease, as it is associated with more axial damage and functional impairment.

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.